Vitro Biopharma Names Chris Furman Chief Executive Officer

July 18, 2022

Golden, Colorado, July 18, 2022 - Vitro Biopharma Inc. is pleased to announce Chris Furman as Chief Executive Officer and the newest member of the company’s Board of Directors.  

Chris Furman

Mr. Furman is a finance industry leader with more than 25 years’ experience in private and public capital markets. Chris has a proven track record of hiring and mentoring successful teams while also building strong and lasting relationships at the senior executive, C-Suite, and Board level. Prior to joining Vitro Biopharma, in his most recent role, Mr. Furman served as Managing Director at Virtus Investment Partners.

Chris has spent the last 25 years in various leadership roles, serving as Managing Partner at Forum Capital Advisors, a Managing Director at ArrowMark Partners, and a Managing Director at Janus Capital Group.

Dr. Caroline Mosessian, Chair of the Board of Directors, said: “We are delighted to announce Mr. Furman as Vitro Biopharma’s Chief Executive Officer. Chris brings an exceptional understanding of capital markets, driving enterprise value, and a wealth of experience from his various leadership roles over 25 years at Janus, Arrowmark Partners, Forum Capital and Virtus Capital. We have great trust and confidence that Chris is the leader who will guide Vitro Biopharma to its next level of excellence. The Board and entire executive team will support Chris as they work together to ensure a successful and exciting future for Vitro Biopharma.”

Mr. Furman commented: “This is an incredibly exciting time in the industry.  I am honored to be a part of the Vitro Biopharma team, lead their growth, and create shareholder value based on 25 years of research.”

The company’s former Chief Executive Officer, Dr. Jack Zamora, continues to be a director on the company’s Board of Directors and a significant company stockholder. 

About Vitro Biopharma

Vitro Biopharma is an innovative biotechnology company focused primarily in the field of regenerative medicine and cellular therapies, with ancillary focuses in the research services, cosmeceutical and nutraceutical fields.  With respect to our regenerative medicine business, we are leveraging our proprietary technologies to develop novel therapeutic candidates intended to address significant unmet medical needs in multiple disease areas with a focus on autoimmune disorders and inflammatory diseases.


Cautionary Note About Forward-Looking Statements
This press release contains “forward-looking statements” about the Company’s plan of business operations, product research and development activities, and other matters. Such forward-looking statements may be identified by words such as “intends,” “anticipates,” “believes,” “expects,” “hopes,” and other similar words indicating possible future expectations, events or actions. Such forward-looking statements are based on current expectations, assumptions, estimates and projections about our business and our industry, and are not guarantees of our future performance. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the marketplace, general economic conditions, receipt of additional working capital, and the overall state of the biotechnology industry. Most of these factors are outside our control.  You are cautioned not to put undue reliance on forward-looking statements.


Chris Furman
4621 Technology Drive
Golden, CO 80403
Phone: (1) 866–848-7267     
Source: Vitro Biopharma, Inc. 

Also in News

Vitro Biopharma Announces Thomas Ohrt New Chief Financial Officer

January 22, 2024 0 Comments

Golden, Colorado, January 23, 2024 – Vitro Biopharma, Inc., an innovative Biotechnology company announced Thomas W. Ohrt, previously the corporate controller, as Chief Financial Officer, effective January 18, 2024.

Read More

Vitro Biopharma Names John Packs to Board of Directors

September 20, 2022 0 Comments

Golden, Colorado, September 23, 2022 - Vitro Biopharma, Inc. is pleased to announce John Packs as the newest member of the company’s Board of Directors, appointed on August 2, 2022.

Read More